» Articles » PMID: 18303411

Detection of FOXO1 (FKHR) Gene Break-apart by Fluorescence in Situ Hybridization in Formalin-fixed, Paraffin-embedded Alveolar Rhabdomyosarcomas and Its Clinicopathologic Correlation

Overview
Date 2008 Feb 28
PMID 18303411
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Chromosomal translocations of t(2;13)(q35;q14) and t(1;13)(p36;q14), resulting in PAX3-FOXO1 (FKHR) and PAX7-FOXO1 (FKHR) gene fusions, have been found to be specific molecular markers for alveolar rhabdomyosarcomas (ARMS) and can be identified in approximately 80% cases. As the prognosis of ARMS is worse than that of embryonal rhabdomyosarcomas (ERMS), it is important to accurately distinguish between these 2 subtypes. This distinction may be difficult on the basis of morphology alone. To detect the genetic alterations, reverse transcriptase polymerase chain reaction (RT-PCR) or dual-color dual-fusion fluorescence in situ hybridization (FISH) have been used in most studies so far. In this study, we used FOXO1 (FKHR) gene break-apart FISH probe, which can detect both of the translocations involving the FOXO1 gene, and tested 20 cases of rhabdomyosarcoma (RMS) including 6 cases of ARMS, 8 ERMS, 1 pleomorphic type, 5 not otherwise specified (RMS-NOS), and 10 non-RMS sarcomas. A home-brew RT-PCR that could detect both PAX3-FOXO1 and PAX7-FOXO1 was also performed. Four pathologists independently reviewed all RMS and a consensus diagnosis was also reached in discrepant cases. Histologic and molecular findings were correlated with clinical outcomes with an average of a 49-month follow-up. FOXO1 break-apart by FISH was positive in 4 of 6 (66%) ARMS and 2 of 5 (40%) RMS-NOS cases. All other cases, including all ERMS, were negative. RT-PCR assay confirmed all FISH results. While 2 of 6 (33%) RMS patients with a FOXO1 break-apart died of the disease, there were no deaths among the patients with negative result. The FOXO1 gene break-apart FISH probe is a simple and accurate tool to detect the translocations associated with ARMS. As characteristic genetic alterations of ARMS can be identified in 40% of RMS-NOS cases in our study, the FISH assay would provide an additional useful tool in the diagnosis and prognosis of ARMS, and an alternative to RT-PCR.

Citing Articles

Local recurrence management of extremity soft tissue sarcoma.

Serban B, Cretu B, Cursaru A, Nitipir C, Orlov-Slavu C, Cirstoiu C EFORT Open Rev. 2023; 8(8):606-614.

PMID: 37526250 PMC: 10441250. DOI: 10.1530/EOR-23-0095.


Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas.

Mota M, Sweha S, Pun M, Natarajan S, Ding Y, Chung C Proc Natl Acad Sci U S A. 2023; 120(18):e2221175120.

PMID: 37094128 PMC: 10161095. DOI: 10.1073/pnas.2221175120.


Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma.

Wei Y, Qin Q, Yan C, Hayes M, Garcia S, Xi H Nat Cancer. 2022; 3(8):961-975.

PMID: 35982179 PMC: 10430812. DOI: 10.1038/s43018-022-00414-w.


Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms.

Luk P, Selinger C, Cooper W, Mahar A, Palme C, OToole S Head Neck Pathol. 2018; 13(3):397-414.

PMID: 30467669 PMC: 6684702. DOI: 10.1007/s12105-018-0988-1.


Diagnosis and treatment of soft-tissue sarcomas of the extremities and trunk.

Smolle M, Andreou D, Tunn P, Szkandera J, Liegl-Atzwanger B, Leithner A EFORT Open Rev. 2017; 2(10):421-431.

PMID: 29209518 PMC: 5702952. DOI: 10.1302/2058-5241.2.170005.